Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Otsuka Applies for Mucosta Eye Drop for Dry Eye
November 29, 2010
- Rohto: Record-High Profits despite Flat Sales
November 29, 2010
- Otsuka Applies for Levocarnitine Based on Published Evidence
November 29, 2010
- GSK to Launch Switch OTC Steroidal Agent
November 29, 2010
- Nippon Kayaku Applies for LCH for Exal Based on Data from Public Domain
November 29, 2010
- Oral Ketotifen Products Should Remain in Class 1: JPA
November 29, 2010
- Bristol-Myers Required to Develop Largest Number of Unapproved Drugs/Indications
November 29, 2010
- 64 Amaryl Generics from 28 Companies Listed
November 29, 2010
- Better Understanding of Etiology Essential to Develop Effective Anti-AD Drugs: Dr Iwai of Astellas
November 29, 2010
- New Premiums for Dispensing Generics Boost Sales of Top-4 Generic Makers
November 29, 2010
- Indacaterol as Effective as Tiotropium: Novartis
November 29, 2010
- Takara Bio: Sales Down 2.9%, Instrument Business in Slump
November 29, 2010
- Sawai: Strong Sales to Pharmacies Boost Sales, Profits
November 29, 2010
- Eisai Enters into Research Collaboration with FORMA
November 29, 2010
- Takata to Comarket Ecbarl with Shionogi
November 22, 2010
- Asahi Kasei Pharma: Sales Remain Flat Despite Strong Sales of Recomodulin
November 22, 2010
- Janssen Voluntarily Recalls Anticancer Drug Velcade
November 22, 2010
- MTPC to Launch Nearly 10 New Products by FY2015
November 22, 2010
- JT: Pharma Business Driven by Torii
November 22, 2010
- Sales of Ethical Drugs Up 0.2% in September: Crecon Report
November 22, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…